Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P lessened its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 16.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 280,166 shares of the medical equipment provider’s stock after selling 55,862 shares during the quarter. Loomis Sayles & Co. L P owned about 0.40% of Lantheus worth $30,748,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of LNTH. Signaturefd LLC increased its position in Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 92 shares in the last quarter. Silverberg Bernstein Capital Management LLC grew its holdings in shares of Lantheus by 0.4% during the second quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock worth $1,834,000 after buying an additional 100 shares in the last quarter. UMB Bank n.a. raised its position in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after buying an additional 126 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Lantheus by 45.5% during the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after buying an additional 146 shares during the period. Finally, Moody National Bank Trust Division grew its stake in Lantheus by 1.1% in the 2nd quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock worth $1,203,000 after acquiring an additional 162 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. JMP Securities lowered their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a report on Thursday, November 7th. Redburn Atlantic started coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective on the stock. Finally, Truist Financial reaffirmed a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $122.50.

Lantheus Trading Up 0.5 %

LNTH opened at $90.96 on Tuesday. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The firm has a market cap of $6.32 billion, a price-to-earnings ratio of 15.13 and a beta of 0.51. The company has a fifty day simple moving average of $103.13 and a 200 day simple moving average of $96.93.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.